Given the frequent presence of activating MYD88 mutations in ABC-DLBCL and a resulting overactivation of the NF-κB pathway, Bruton’s tyrosine kinase (BTK) inhibitors -which can block downstream NF-κB- have been used in second line treatment of ABC-DLBCL [33–35]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.